FO
ESPR

FT Options’s Esperion Therapeutics ESPR Stock Holding History

FT Options’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$2K Sell
7,800
-55,200
-88% -$2.66M ﹤0.01% 210
2017
Q2 		$17K Sell
63,000
-5,000
-7% -$184K 0.03% 141
2017
Q1 		$17K Buy
+68,000
New +$1.56M 0.02% 205
2016
Q4 		– Sell
-23,200
Closed -$35K – 285
2016
Q3 		$35K Buy
+23,200
New +$263K 0.03% 239

Other funds holding ESPR

MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

FT Options's ESPR Position: Q3 2017 in Review

FT Options opened a new position in Esperion Therapeutics (ESPR) in Q3 2017: 8,825 shares worth $442K. The stake represents 0.67% of the portfolio and ranks #48 among its holdings. This is a return to the name: FT Options previously reported a position in ESPR as recently as Q1 2017.

FT Options first reported a position in ESPR in Q4 2015 and has held it in 6 quarters since. The position peaked at $806K in Q1 2017. 150 funds tracked by Wall St. Rank hold ESPR as of Q3 2017.

  • FT Options held 8,825 shares of Esperion Therapeutics worth $442K as of Q3 2017.
  • Esperion Therapeutics was a new FT Options position in Q3 2017.
  • Esperion Therapeutics made up 0.67% of FT Options's portfolio in Q3 2017, its #48 holding.
  • FT Options first reported a position in Esperion Therapeutics in Q4 2015 and has held it in 6 quarters since.
  • FT Options's Esperion Therapeutics position peaked at $806K in Q1 2017.
  • 150 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.